Company intelligence / Profile preview
Fe Pharmaceuticals
Redwood City, California, USAfepharm.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
DIBI has shown proof-of-concept in various infectious and inflammatory disease models with 27 peer-reviewed publications. It has demonstrated potent, broad-spectrum antimicrobial activity against fungal and bacterial infections, including drug-resistant organisms. In animal models of sepsis, DIBI down-regulated excess cytokine release and promoted survival, acting synergistically with antibiotics.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Iron-binding copolymer
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Fe Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fe Pharmaceuticals.